Compare NWE & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWE | TLX |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | NWE | TLX |
|---|---|---|
| Price | $64.84 | $7.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $60.00 | $21.00 |
| AVG Volume (30 Days) | ★ 584.8K | 203.3K |
| Earning Date | 02-11-2026 | 01-15-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.53 | 0.04 |
| Revenue | ★ $1,569,761,000.00 | $664,225,558.00 |
| Revenue This Year | $6.15 | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | ★ $18.29 | $175.66 |
| Revenue Growth | 4.90 | ★ 55.35 |
| 52 Week Low | $50.46 | $7.49 |
| 52 Week High | $69.23 | $30.36 |
| Indicator | NWE | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 28.22 |
| Support Level | $64.09 | $7.72 |
| Resistance Level | $65.23 | $8.22 |
| Average True Range (ATR) | 1.13 | 0.22 |
| MACD | -0.22 | -0.06 |
| Stochastic Oscillator | 36.80 | 0.78 |
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric utility operations, which include the generation, purchase, transmission, and distribution of electricity, and Natural Gas utility operations, which include the production, purchase, transmission, storage, and distribution of natural gas. The company uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric utility operations segment.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.